Literature DB >> 3998199

Nifedipine in the treatment of hypertension in the elderly.

J Stessman, B Leibel, Y Yagil, R Eliakim, D Ben-Ishay.   

Abstract

The effect of nifedipine monotherapy, retard tablets, 20 mg bid, was evaluated in 23 hypertensive patients, mean age, 79 +/- 2 years. Twenty-one patients completed an eight-week study. Blood pressure (BP) decreased to 160/90 mm Hg in 15 patients; in four additional patients diastolic BP dropped by 15% to 28%. In a subset of five patients with isolated systolic hypertension, a significant reduction in systolic BP was noted. Side effects were relatively mild and only two patients discontinued the study. The results suggest that nifedipine monotherapy offers an alternative, logic, therapeutic approach to hypertension in the elderly.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998199     DOI: 10.1002/j.1552-4604.1985.tb02824.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Hypertension in the elderly.

Authors:  P Larochelle
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  The treatment of hypertension in the elderly.

Authors:  M Chellingsworth; D G Beevers
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

Review 3.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

4.  Behavioral performance effects of nifedipine in normotensive and renovascular hypertensive baboons.

Authors:  J S Turkkan; R D Hienz
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Dose adjustment of nifedipine in hypertensive patients.

Authors:  N Bacracheva; P Thuermann; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.